Wenshi Wang, MD, PhD
Wenshi Wang brings both international and American institutional drug development experience to her role at Metagenomi, with experience in various roles in Germany, City of Hope, USC Keck, Children’s Hospital Los Angeles, Moffit Cancer Institute and Kite Pharma.
VP of Cell Therapy Development
Most recently, Wenshi served as Senior Director at Sangamo Therapeutics leading the cell therapy pharmaceutical development department for CAR-Treg, gene modified CD34 and iPSC platform development. At Kite Pharma, Wenshi contributed development process and assay development for IND filing on CAR T and TCR T products. She has made significant contributions to many successful filings with agencies (Interact, Pre-IND, IND/IMPD, Pre-BLA).
Wenshi has nearly a decade’s experience in pre-clinical, phase I, II and III investigations and biomarkers studies at Moffitt Cancer Center and the University of Southern California.
Wenshi holds a PhD in Microbiology & Immunology from Huazhong Science & Technology University, China and a MD in Clinical Medicine from Tianjin Medical University. She also has a U.S. Patent for her Biomarker work.